In re Loestrin 24FE Antitrust Litigation

In the wake of the Supreme Court’s landmark decision in FTC v. Actavis, Goodwin attorneys have been at the forefront of litigating antitrust challenges to settlement agreements between brand and generic pharmaceutical companies. In this case, Goodwin filed an amicus brief on behalf of the Association for Accessible Medicines (formerly known as the Generic Pharmaceutical Association) arguing that patent challenges settled through the grant of an early-entry exclusive licenses benefit consumers and should not be subjected to antitrust challenges.

In re Loestrin 24FE Antitrust Litigation

Download PDF

Leave a reply

Your email address will not be published. Required fields are marked *